Benzinga··Vandana SinghAbbVie's Obesity Drug Shows Promise With Up to 10% Weight Loss in Early Trial
AbbVie reports Phase 1 data for obesity treatment ABBV-295, showing 7.75%-9.79% weight loss. Stock declined despite positive results amid broader market pressure.
ABBVXLVIYHclinical trialweight loss